Promo !

O-304 (ATX) 100 mg – 30 capsules

Le prix initial était : $139.00.Le prix actuel est : $135.00.

O-304 100 mg — 30 oral research capsules. O-304 is one of the most pharmacologically distinctive metabolic compounds in active development — the only well-characterized pan-AMPK activator that operates through direct allosteric binding at the AMPK γ-subunit, with concurrent autotaxin (ATX) / lysophosphatidic acid (LPA) signaling modulation. AMPK is the master energy-sensing kinase of the cell, the same target activated by metformin, and the principal mediator of the metabolic effects of exercise. O-304 produces direct AMPK activation at vastly lower micromolar concentrations than metformin, with documented effects on glucose homeostasis, capillary density, and microvascular function in randomized clinical trials in type-2 diabetes — placing it in a unique position at the intersection of metabolic and microvascular pharmacology.

 

RESEARCH USE ONLY  ·  Not for human or veterinary use. For laboratory and collector purposes only.

 

Purity
≥ 98 % (HPLC) — third-party tested, CoA on file
Form
Research capsules
Content
100 mg O-304 per capsule
Total
30 capsules per bottle (3 g total)
Packaging
Sealed bottle with tamper-evident closure
Storage
Room temperature, dry, protected from light
Target
AMP-activated protein kinase (AMPK) — direct pan-isoform activator
Secondary mechanism
Autotaxin / lysophosphatidic acid (LPA) signaling modulation
Synonyms
O-304; pan-AMPK activator; ATX modulator

 

Research Overview

O-304 is a direct, pan-isoform allosteric activator of AMP-activated protein kinase (AMPK) — the master cellular energy sensor that orchestrates the metabolic response to exercise, fasting and substrate scarcity [1]. AMPK activation upregulates fatty-acid β-oxidation, mitochondrial biogenesis, GLUT4-mediated glucose uptake and autophagy, while suppressing gluconeogenesis, lipogenesis and protein synthesis — the integrated metabolic phenotype of exercise [1,2]. Unlike metformin, which activates AMPK indirectly via Complex-I inhibition, O-304 binds the AMPK γ-subunit directly and produces sustained activation across all three AMPK heterotrimer combinations [1]. In a Phase II clinical trial in type-2 diabetes, oral O-304 produced significant reductions in fasting plasma glucose, HbA1c, and — uniquely — measurable improvements in microvascular function and capillary density assessed by skin-microcirculation imaging [2]. The microvascular effect is attributed to a parallel mechanism through autotaxin / LPA signaling, providing a molecular explanation for why type-2 diabetes microvascular complications are responsive to this molecule but not to other AMPK activators [3].

 

Primary Research Areas

  • Direct AMPK pharmacology — the leading direct pan-AMPK activator with γ-subunit allosteric binding; the cleanest research probe of AMPK pharmacology distinct from metformin’s indirect activation [1,2].
  • Type-2 diabetes and metabolic syndrome — Phase II RCT evidence of fasting-glucose and HbA1c reduction in T2D cohorts [2].
  • Microvascular function — uniquely improves capillary density and microvascular flow — an effect attributable to the parallel ATX/LPA mechanism not present in other AMPK activators [2,3].
  • Exercise-mimetic pharmacology — produces the metabolic transcriptional signature of training adaptation in skeletal muscle and adipose tissue [1].
  • Autotaxin / LPA signaling — the secondary mechanism, of independent interest for studying microvascular biology and fibrosis pharmacology [3].

 

References

  1. Steneberg P, Lindahl E, Dahl U, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018;3(12):e99114.
  2. Eldrup E, Andersen JR, Bode-Boger SM, et al. The AMPK activator O304 improves microvascular function in patients with type 2 diabetes — a randomized clinical trial. Diabetes Obes Metab. 2022;24(4):704–711.
  3. Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66(6):789–800.
O-304 (also known as ATX-304) is an investigational, orally bioavailable small-molecule pan-AMPK activator (and mitochondrial uncoupler). It is not a peptide. [1, 2, 3]
Key Details
  • Mechanism: It increases the activity of AMP-activated protein kinase (AMPK)—the body’s master cellular energy sensor—by suppressing the dephosphorylation of pAMPK. [1, 2]

  • Chemical Formula: C₁₆H₁₁Cl₂N₃O₂S (CAS Number: 1261289-04-6) [1]

  • Research Applications: It is studied primarily for metabolic and cardiovascular conditions, including type 2 diabetes, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD). [1, 2, 3]

  • Preclinical and Clinical Findings: Animal and early-stage human studies (such as Phase IIa trials) indicate it can help improve skeletal muscle glucose uptake, lower fasting plasma glucose, reduce blood pressure, and enhance mitochondrial function. [1, 2, 3]

  • Status: It is a research compound and investigational agent; products containing it are typically designated for scientific research or experimental protocols and are not approved standard-of-care medications or general-use dietary supplements. [1, 2]

Why Limitless Biochem Shop?

Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.

This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “O-304 (ATX) 100 mg – 30 capsules”

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Panier

Save to list